Pill 'Melts Away' Leukemia, Scientists Report

Friday, 24 Jan 2014 03:31 PM

By Nick Tate

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
A pill taken twice a day could turn a common and deadly form of leukemia into a manageable disease that is treated as easily as high blood pressure, a new international suggests.
 
In research published in this week's New England Journal of Medicine, scientists led by Weill Cornell Medical College determined the drug idelalisib can "melt away" chronic lymphocytic leukemia (CLL), allowing patients to avoid having to take debilitating chemotherapy.

Editor's Note: Knowing these 5 cancer-causing signs is crucial to remaining cancer-free for life
 
CLL is the most common form of the blood cancer, striking 16,000 Americans each year and killing 5,000 annually. Current treatment involves chemotherapy, but it is highly toxic and carries significant side effects.
 
"The treatment today for CLL can be worse than the disease, leading to a great deal of side effects and death. This study, and others we have conducted on idelalisib, demonstrates that we may no longer need to use chemotherapy in CLL," said lead investigator Richard R. Furman, M.D., a professor at Weill Cornell Medical College and an oncologist at NewYork-Presbyterian/Weill Cornell Medical Center. "Even if this cancer remains incurable, it now can be treated as if it was a chronic disease with a pill, in the same way that high blood pressure is treated."
 
For the study, researchers from 19 medical centers in five countries tested a combination of two targeted drugs — comparing rituximab and idelalisib against rituximab and a placebo pill in 220 patients.
 
They found that those who received the combination of idelalsib and rituximab fared better than those who received only rituximab. Six months into the study, cancers in 93 percent of participants in the combination therapy group had not worsened, compared to 46 percent of those in the rituximab plus placebo group.
 
What's more, just 13 percent of patients treated with rituximab alone responded to the therapy, compared to 81 percent of the participants in the idelalisib treatment group. A higher percentage of patients who received both drugs – some 92 percent – were still alive a year after the study began, compared to 80 percent of those who only received rituximab.
 
"We saw incredible responses in patients who used idelalisib. Their cancer quickly melted away," said Dr. Furman. "These types of responses were even seen in patients who didn't respond to chemotherapy."

Editor's Note: Knowing these 5 cancer-causing signs is crucial to remaining cancer-free for life

© 2014 NewsmaxHealth. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink

 
Email:
Retype Email:
Country
Zip Code:
 
Find Your Condition
Follow Newsmax

You May Also Like

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

NEWSMAXHEALTH.COM
© Newsmax Media, Inc.
All Rights Reserved